ZAI Builds On Sanofi Ties For Lung Cancer Candidate
This article was originally published in PharmAsia News
China’s ZAI Lab has in-licensed its third preclinical drug candidate from Sanofi, a novel multi-kinase inhibitor aimed at a non-small cell lung cancer target and other oncology indications. The new agreement indicates ZAI’s R&D strategy of bringing in novel early stage assets with large unmet needs in China and globally.
You may also be interested in...
Hanmi is reviewing a new global clinical trial plan for its novel lung cancer drug olmutinib after China's ZAI Lab returned its rights, and following Boehringer’s cancellation of a major-licensing deal in 2016. ZAI's decision may reflect the difficulties faced by olmutinib and other third generation EGFR inhibitors in competing with Tagrisso, as well as the increasingly crowded and rapidly changing non-small cell lung cancer space.
Leveraging the brain power behind the first approved IPF drug, Esbriet, small companies Antegrin and Cascadia merge to form the fibrosis-centered Indalo Therapeutics. Gedeon Richter in-licenses a biosimilar of Roche’s Herceptin.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.